Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Relicann** is a proprietary hemp-based cannabidiol product brand from Revive Therapeutics, with the specifically described product being a controlled-release chewing gum formulation that contains hemp oil and cannabidiol for the health and wellness and medical cannabis market. Publicly available company materials describe it as a cannabinoid delivery product rather than an approved prescription pharmaceutical, using oral mucosal delivery through chewing gum to improve cannabinoid absorption and bioavailability. The explicitly identifiable active drug substance is cannabidiol derived from hemp; however, Relicann appears to function primarily as a brand/platform name for a cannabinoid wellness product line rather than a clearly defined approved drug with a well-established clinical indication or regulatory approval as a pharmaceutical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Relicann.